Clinical Trials
1144
157 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1966
Active, not recruiting
3
0.3%
Completed
653
57.1%
Not yet recruiting
154
13.5%
Recruiting
304
26.6%
Suspended
1
0.1%
Unknown
1
0.1%
Withdrawn
28
2.5%
No approval data available
- Bayer and Vanderbilt University Medical Center announced a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug application. - The partnership will initially focus on cardiovascular and kidney diseases, two therapeutic areas with significant unmet medical need, while spanning across all indications currently pursued by Bayer. - The collaboration will leverage VUMC's comprehensive datasets, including the BioVU collection of DNA and plasma, to enable data-driven insights and accelerate drug discovery and development. - The agreement combines Bayer's expertise in drug discovery and translational sciences with VUMC's deep preclinical and clinical knowledge to advance precision medicine approaches.
- A Vanderbilt study demonstrates that AI-powered interruptive alerts led to 42% suicide risk assessment completion rate compared to 4% with passive alerts in neurology clinics. - The VSAIL model analyzes electronic health records to identify high-risk patients, flagging only 8% of total visits for targeted screening, making implementation feasible in busy clinical settings. - Research validates the system's efficiency in neurology clinics, where certain conditions correlate with increased suicide risk, with no reported adverse events during the 30-day follow-up period.
